Biologics

Scotland
#Biologics #Dermatology #Novartis #Scottish Medicines Consortium (SMC)

New biologic approved in Scotland for hidradenitis suppurativa

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The advice applies for use in adult patients with… Read More

#News #Regulatory

amino acids chain
#Biologics #Drug discovery #Infographic #Nanomedicine / nanotechnology #Proteins

Compare methods for thermal stability assessment of proteins

A new infographic ‘Four methods for thermal stability assessment of therapeutic proteins‘ is now available to download for free. Thermal stability is among the most common critical quality attributes (CQAs) used for early developability assessment of biologics. In this infographic, learn about four methods for thermal stability… Read More

#News

#Biologics #Drug discovery #Infographic #Nanomedicine / nanotechnology #Proteins

Four methods for thermal stability assessment of proteins

Thermal stability is among the most common critical quality attributes (CQAs) used for early developability assessment of biologics. In this infographic, learn about four methods for thermal stability assessment of proteins – what they measure, what the data tells you, and their benefits and limitations. While each provides unique value,… Read More

#Intelligence #Resources

Human cell
#Biologics #Cell and gene therapy #Cytomos #Lab technology #Single-cell analysis

Can cell analysis tech help streamline biotech product development?

Scotland-based biotech Cytomos has launched its newly patented AuraCyt cell analysis technology brand. According to the company, AuraCyt provides information on cell properties and can be incorporated in-line, allowing real-time monitoring of cell manufacturing events and predicting manufacturing success. It is designed to collect data that measures the intrinsic properties… Read More

#Business & Investment #News

#Biologics #GlobalData #Inflammatory Bowel Disease #Market reporting #Small molecules

Biologics for bowel disease face threat from cheaper small molecules

The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received… Read More

#Market Reports #News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

PEGS Europe posters
#Antibodies #Antibody discovery workflow #Biologics #Drug discovery #Events #PEGS Europe 2023 #Protein engineering

Reflecting on PEGS Europe 2023 

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. Here, she shares insight from the annual biologics technology meeting.   Scientific tracks and presentations  Antibody-based cancer therapies   The first presentation attended in the antibody-based cancer therapies track, within the antibody drug… Read More

#Exclusive Content

#Biologics #Biology #Dewpoint Therapeutics #Partnership

Podcast: In conversation with Isaac Klein, CSO, Dewpoint Therapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Isaac Klein, Chief… Read More

#News

Lisbon skyline
#Antibodies #Antibody drug conjugate (ADC) #Biochemistry #Biologics #Biologics / Biotechnology #Bispecific Antibodies #Combination therapy #Engineered antibodies #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 1

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific… Read More

#Exclusive Content

FDA approval
#Biologics #FDA #Rare disease #Rocket Pharmaceuticals

FDA acceptance advances investigational gene therapy 

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).  Rocket Pharmaceuticals is a late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need. RP-L201 is a lentiviral vector… Read More

#News #Regulatory

Biologics research
#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Characterisation of candidates during biologic development

Download the new Infographic from NanoTemper: ‘Stability assessment of biologics during early development workflows‘. During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure… Read More

#News

#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Stability assessment of biologics during early development workflows

During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure in its buffer, and whether it remains that way over time. Biophysical characterisations are valuable for providing… Read More

#Intelligence #Resources

Antibody
#Acute inflammatory conditions #Antibody #Autoimmune disease #Biologics

Novel antibody displays potent anti-inflammatory activity

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F… Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR #Whitepaper

Whitepaper on digital PCR for lentiviral vector characterisation

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

CAR-T therapy
#Aleta Biotherapeutics #Biologics #Cancer research #Cancer Research UK #CAR-T #MHRA #Oncology

Biologic CAR-T cell engager approved for UK clinical trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for… Read More

#Cancer Research #News #Regulatory